tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

IMCR Stock Latest News

Immunocore presents Phase 1 data of brenetafusp in ovarian cancer
The FlyImmunocore presents Phase 1 data of brenetafusp in ovarian cancer
4d ago
IMCR
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
PremiumPress Releases
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
5d ago
IMCR
Immunocore to present at the 2024 Cantor Global Healthcare Conference
PremiumPress Releases
Immunocore to present at the 2024 Cantor Global Healthcare Conference
7d ago
IMCR
Immunocore CFO Brian Di Donato to depart
PremiumThe Fly
Immunocore CFO Brian Di Donato to depart
21d ago
IMCR
Immunocore price target raised to $89 from $87 at Oppenheimer
PremiumThe Fly
Immunocore price target raised to $89 from $87 at Oppenheimer
1M ago
IMCR
Immunocore price target lowered to $66 from $92 at Barclays
PremiumThe FlyImmunocore price target lowered to $66 from $92 at Barclays
1M ago
IMCR
Immunocore price target lowered to $70 from $90 at Jefferies
Premium
The Fly
Immunocore price target lowered to $70 from $90 at Jefferies
1M ago
IMCR
Immunocore reports Q2 EPS (23c), consensus (48c)
Premium
The Fly
Immunocore reports Q2 EPS (23c), consensus (48c)
1M ago
IMCR
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
PremiumPress Releases
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
2M ago
IMCR
Immunocore announces randomization of first patient in Phase 3 brenetafusp trial
PremiumThe Fly
Immunocore announces randomization of first patient in Phase 3 brenetafusp trial
3M ago
IMCR
Immunocore presents KIMMTRAK clinical data at ASCO 2024
PremiumThe Fly
Immunocore presents KIMMTRAK clinical data at ASCO 2024
4M ago
IMCR
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
PremiumPress Releases
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
4M ago
IMCR
Immunocore Reveals Promising Brenetafusp Trial Results
PremiumCompany AnnouncementsImmunocore Reveals Promising Brenetafusp Trial Results
4M ago
8K
IMCR
Immunocore reports updated brenetafusp data
Premium
The Fly
Immunocore reports updated brenetafusp data
4M ago
IMCR
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
Premium
Press Releases
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
4M ago
IMCR
Immunocore to present at the Jefferies Global Healthcare Conference
PremiumPress Releases
Immunocore to present at the Jefferies Global Healthcare Conference
4M ago
IMCR
Immunocore converts Phase 2/3 TEBE-AM trial into registrational Phase 3 trial
PremiumThe Fly
Immunocore converts Phase 2/3 TEBE-AM trial into registrational Phase 3 trial
4M ago
IMCR
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
PremiumPress Releases
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
4M ago
IMCR
Immunocore Bolsters Board and Strikes Deal with BBA Funds
PremiumCompany Announcements
Immunocore Bolsters Board and Strikes Deal with BBA Funds
4M ago
8K
IMCR
Immunocore price target lowered to $88 from $90 at Mizuho
PremiumThe FlyImmunocore price target lowered to $88 from $90 at Mizuho
4M ago
IMCR
Immunocore price target raised to $100 from $90 at H.C. Wainwright
Premium
The Fly
Immunocore price target raised to $100 from $90 at H.C. Wainwright
4M ago
IMCR
Immunocore price target raised to $67 from $63 at Canaccord
Premium
The Fly
Immunocore price target raised to $67 from $63 at Canaccord
4M ago
IMCR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >